PYC Therapeutics Croissance future

Future contrôle des critères 1/6

PYC Therapeutics devrait augmenter ses bénéfices et son chiffre d'affaires de 34.7% et de 15.6% par an respectivement. Le BPA devrait croître de de 5.3% par an. Le rendement des capitaux propres devrait être -28.5% dans 3 ans.

Informations clés

34.7%

Taux de croissance des bénéfices

5.3%

Taux de croissance du BPA

Biotechs croissance des bénéfices	15.3%
Taux de croissance des recettes	15.6%
Rendement futur des capitaux propres	-28.4%
Couverture par les analystes	Low
Dernière mise à jour	18 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)

Feb 20

Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?

Jan 26

What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition

Dec 22

We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth

Nov 17

Prévisions de croissance des bénéfices et des revenus

ASX:PYC - Estimations futures des analystes et données financières antérieures (AUD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
6/30/2027	35	-13	-19	1	4
6/30/2026	35	-19	-37	-29	4
6/30/2025	9	-48	-39	-44	4
6/30/2024	22	-38	-39	-39	N/A
3/31/2024	22	-30	-29	-29	N/A
12/31/2023	21	-22	-20	-19	N/A
9/30/2023	19	-22	-22	-22	N/A
6/30/2023	16	-23	-25	-24	N/A
3/31/2023	15	-23	-26	-25	N/A
12/31/2022	14	-24	-26	-26	N/A
9/30/2022	15	-19	-24	-24	N/A
6/30/2022	16	-14	-22	-22	N/A
3/31/2022	13	-15	-18	-17	N/A
12/31/2021	9	-17	-14	-13	N/A
9/30/2021	6	-17	-13	-12	N/A
6/30/2021	3	-18	-12	-12	N/A
3/31/2021	3	-15	-11	-11	N/A
12/31/2020	2	-12	-10	-10	N/A
9/30/2020	2	-9	-8	-8	N/A
6/30/2020	2	-7	-6	-6	N/A
3/31/2020	1	-6	-6	-6	N/A
12/31/2019	0	-5	-6	-6	N/A
9/30/2019	0	-5	-6	-6	N/A
6/30/2019	N/A	-4	-6	-5	N/A
3/31/2019	0	-4	-4	-4	N/A
12/31/2018	0	-5	-3	-3	N/A
9/30/2018	0	-6	-5	-5	N/A
6/30/2018	0	-7	-7	-7	N/A
3/31/2018	0	-6	N/A	-5	N/A
12/31/2017	0	-5	N/A	-3	N/A
9/30/2017	1	-3	N/A	-3	N/A
6/30/2017	3	-2	N/A	-2	N/A
3/31/2017	3	-3	N/A	-4	N/A
12/31/2016	3	-4	N/A	-6	N/A
9/30/2016	1	-4	N/A	-5	N/A
6/30/2016	0	-4	N/A	-3	N/A
3/31/2016	0	-4	N/A	-2	N/A
12/31/2015	0	-4	N/A	-1	N/A
9/30/2015	0	-3	N/A	-2	N/A
6/30/2015	1	-3	N/A	-2	N/A
3/31/2015	1	-3	N/A	-3	N/A
12/31/2014	1	-3	N/A	-4	N/A
9/30/2014	1	-3	N/A	-4	N/A
6/30/2014	1	-3	N/A	-3	N/A
3/31/2014	1	-3	N/A	-3	N/A
12/31/2013	1	-3	N/A	-3	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: PYC devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: PYC devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: PYC devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de PYC ( 15.6% par an) devrait croître plus rapidement que le marché Australian ( 5.7% par an).

Croissance élevée des revenus: Le chiffre d'affaires de PYC ( 15.6% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: PYC devrait être non rentable dans 3 ans.

PYC Therapeutics Croissance future

Future contrôle des critères 1/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased by 8.2% to AU$0.33

Price target increased by 9.1% to AU$0.30

Price target decreased by 15% to AU$0.29

Forecast to breakeven in 2026

Recent updates

New minor risk - Market cap size

We're Hopeful That PYC Therapeutics (ASX:PYC) Will Use Its Cash Wisely

Price target increased by 8.2% to AU$0.33

PYC Therapeutics Limited, Annual General Meeting, Nov 13, 2024

Price target increased by 9.1% to AU$0.30

Insufficient new directors

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Price target decreased by 15% to AU$0.29

PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 74.657302 million.

Forecast to breakeven in 2026

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 74.657343 million.

New major risk - Financial position

Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease

Is PYC Therapeutics (ASX:PYC) In A Good Position To Deliver On Growth Plans?

PYC Therapeutics Limited, Annual General Meeting, Nov 24, 2023

New minor risk - Financial data availability

PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development Program

New minor risk - Share price stability

We Think PYC Therapeutics (ASX:PYC) Needs To Drive Business Growth Carefully

Non-Executive Chair of the Board recently bought AU$85k worth of stock

PYC Therapeutics Limited, Annual General Meeting, Jul 05, 2023

Pyc Appoints Andrew Taylor as Joint Company Secretary

PYC Therapeutics Limited Announces the Submission of Investigational New Drug Application with the US Food and Drug Administration

Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation

High number of new and inexperienced directors

PYC Therapeutics Limited Announces Successful Toxicology Studies Pave Way for Human Trials

PYC Therapeutics Limited, Annual General Meeting, Nov 23, 2022

PYC Therapeutics Limited Announces Central Nervous System Drug Program Added to PYC Pipeline

Non-Executive Chair of the Board recently bought AU$103k worth of stock

PYC Therapeutics Limited Announces Exemplary PK Study Results Move RP11 Program Closer to First in Human Trials

High number of new and inexperienced directors

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

PYC Therapeutics Limited Enters into the Next Phase of Preclinical Development for VP-001

PYC Therapeutics Announces Comprehensive Preclinical Results Demonstrating VP-002 Program's Potential as the First Disease Modifying Therapy for Autosomal Dominant Optic Atrophy

CEO & Director exercised options to buy AU$1.6m worth of stock.

PYC Therapeutics to Develop A New Generation of RNA Therapeutics

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease ­ Autosomal Dominant Optic Atrophy

We're Not Very Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Rate

PYC Therapeutics Limited Appoints Michael Rosenblatt, MD, to Its Board of Directors

PYC's Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Models - a First for Any Rp11 Treatment to-Date

PYC Therapeutics Names Glenn Noronha as Chief Development Officer

Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)

Non-Executive Chair of the Board recently bought AU$81k worth of stock

Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?

What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition

PYC Therapeutics Limited Announces Visual Evidence of Lead Drugs Efficacy

PYC Therapeutics Limited Appoints Sahm Nasseri as CEO of Us Operations and as Director of the Board

We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth

PYC Therapeutics Announces to Developing New Treatments for Severe Unmet Patient Needs

Doug Huey Not to Seek Re Election At PYC Therapeutics Limited

PYC Therapeutics Limited Develops New Treatments for Severe Unmet Patient Needs

PYC Therapeutics Limited Files for Intellectual Property Protection for the New Drug Candidate

PYC Therapeutics Limited Announces CEO Changes

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease Autosomal Dominant Optic Atrophy